BioSpace News Archive

Rejuvenate Bio today announced the appointments of Hugh Calkins, M.D., Stephen Chelko, Ph.D., and Dr. Elif Oral, M.D., to its Scientific Advisory Board (SAB).

Zymeworks Inc. today announced that management will participate in upcoming investor conferences.

GC Aesthetics® (GCA®) a privately-held medical technology company providing aesthetic and reconstructive solutions for women’s global healthcare markets is proud to announce the CE approval of the new micro-textured anatomical breast implant LUNA xt™, the first breast implant in the world approved under the new European Medical Device Regulation (MDR).

Enanta Pharmaceuticals, Inc. today announced the initiation of a Phase 2b, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of EDP-938, its novel N-protein inhibitor, in adults with acute respiratory syncytial virus (RSV) infection who are at high risk of complications.

Labcorp (NYSE: LH), a leading global life sciences company, today announced the completion of transactions that establish a long-term laboratory relationship with Ascension, one of the leading non-profit and Catholic health systems in the United States.

Acerus Pharmaceuticals Corporation today announced that it has amended the promissory note (the “ Note ”) in the amount of US$4.91 million related to the up-front fee owed to former Serenity Pharmaceuticals LLC (“Serenity”) securityholders.

Sol-Gel Technologies, Ltd. announced today the appointment of Michael Glezin to the position of Vice President, Business Development.

Aclarion, Inc. announced today that John Keller M.D., Chief of Neurosurgery at University of Michigan Health-West and Neurosurgeon at Great Lakes Neurosurgical Associates in Grand Rapids, MI, will advise the company as a Key Opinion Leader (KOL) in the greater Michigan market.

OpGen, Inc. today announced its successful completion of patient enrollment for its clinical trial for the Unyvero Urinary Tract Infection (UTI) Panel.

Venatorx Pharmaceuticals today announced the Biomedical Advanced Research and Development Authority has awarded the company a contract to support the development of cefepime-taniborbactam for the treatment of melioidosis.